ArticleLipids in health and disease2026
Association between glycolipid metabolism 7 factors (GLM7) and pregnancy loss in women aged 18-35 years: evidence from NHANES 2009-2018.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowing evidence suggests that metabolic disturbances underlie pregnancy losses, imposing a substantial public health burden among young women of reproductive age. Glycolipid metabolism 7 factors (GLM7) is a composite glycolipid metabolism index derived from routinely measured metabolic indicators; however, its relevance to pregnancy loss in young women remains unexamined.
methodsThe present study analyzed publicly available data from the 2009-2018 National Health and Nutrition Examination Survey (NHANES) cycles. Participants were categorized as having no pregnancy loss, single pregnancy loss, or recurrent pregnancy loss (≥ 2 losses). GLM7 was calculated as the logarithm of the product of age, body mass index, fasting blood glucose, fasting insulin, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels. The association between GLM7 and pregnancy loss categories was evaluated, potential dose-response patterns were explored, and effect modification by selected sociodemographic and behavioral factors was assessed.
resultsOf the 736 women included in the analysis, 300 (37%) reported a history of pregnancy loss. In binary analyses, higher GLM7 was initially associated with pregnancy loss (OR = 1.21, 95% CI: 1.03-1.44); however, the association was attenuated after adjustment for the number of pregnancies (OR = 1.19, 95% CI: 0.99-1.44). In multinomial analyses, higher GLM7 levels were not significantly associated with single pregnancy loss. In contrast, higher GLM7 remained independently associated with recurrent pregnancy loss after adjustment for all covariates (OR = 1.17, 95% CI: 1.02-1.42; P = 0.046). Women in the second to fourth quartiles had significantly higher odds of recurrent pregnancy loss than those in the lowest quartile. No significant nonlinearity was observed in the association between GLM7 and recurrent pregnancy loss (P for nonlinearity = 0.265). No statistically significant interaction was observed across the subgroups.
conclusionsIn this nationally representative sample of U.S. women aged 18-35 years, higher GLM7 levels were more robustly associated with recurrent rather than isolated pregnancy loss. The findings suggested that cumulative glycolipid metabolic burden may be particularly relevant to repeated reproductive failures and serve as indicators to improved strategies for early reproductive risk identification and preventive healthcare for women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.